Quantifying the Added Value of Low-Molecular-Weight Heparin to Intermittent Pneumatic Compression for Preventing Venous Thromboembolic Events Under the Risk-Benefit Perspective

JAMA Surg. 2019 Mar 1;154(3):270-271. doi: 10.1001/jamasurg.2018.4294.
No abstract available

Publication types

  • Comment

MeSH terms

  • Adenocarcinoma*
  • Gastrectomy
  • Heparin, Low-Molecular-Weight
  • Humans
  • Incidence
  • Intermittent Pneumatic Compression Devices
  • Republic of Korea
  • Venous Thromboembolism*

Substances

  • Heparin, Low-Molecular-Weight